The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by ...
The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...
According to CMS data, Medicare Part D spending ... of Medicare negotiations yielded discounts on drugs ranging from 40 percent to 80 percent, including 76 percent off the list price for NovoLog.
Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...
Teva Pharmaceutical Industries' (NYSE:TEVA) U.S. division has sued CMS over the Medicare ... D.C. federal court, the Israel-based drugmaker says that guidance CMS has issued on price negotiations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback